Effectiveness of Dorocontin and Sustak Drugs

Comparison of Effectiveness of Dorocontin and Sustak Drugs on Treatment of Ischemic Heart Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014051516563N2

Enrollment

140

Registered

2014-08-11

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Chronic Ischaemic Heart Disease. Condition 2: Silent Myocardial Ischaemia. Condition 3: Acute Ischaemic Heart Disease. Condition 4: Acute Ischaemic Heart Disease, Unspecified. Condition 5: Acute Ischaemic Heart Disease, Unspecified. Condition 6: Family History of Ischaemic Heart Disease and Other Diseases of the Circulatory System. Chronic ischaemic heart disease Silent myocardial ischaemia Acute ischaemic heart disease Acute ischaemic heart disease, unspecified Acute ischaemic

Interventions

Intervention 1: 4.6 mg nitrocantin tablets (sustained nitrogycerin) with 3 doses per day for 2 months. Intervention 2: 4.6 mg sustak tablets (sustained nitrogycerin) with 3 doses per day for 2 months.

Treatment - Drugs

4.6 mg nitrocantin tablets (sustained nitrogycerin) with 3 doses per day for 2 months

4.6 mg sustak tablets (sustained nitrogycerin) with 3 doses per day for 2 months

Eligibility

Sex/Gender

All

Age

40 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion: Being higher than 40 years old Having clinical signs of IHD (stable angina) like a chest pain which increases during activities and decreases during rest and usage of drug Exclusion: Having background diseases (diabetes, kidney failure, hyperpressure, & ...) Having clinical and lab signs of unstable angina or anfractuous (ECG changes along with increased levels of cardiac enzymes) Simultaneous drug conflicts and bronchodilators such as calcium channel blockers, sildenafil

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Paintful joints. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;AlkP. Timepoint: after and before treatment. Method of measurement: serologic tests.;LDH. Timepoint: after and before treatment. Method of measurement: serologic tests.;SGOT. Timepoint: after and before treatment. Method of measurement: serologic tests.;Tachypnea. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Dyspnoeic. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Headache. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Organ edema. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Vomiting. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Nausea. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;BUN. Timepoint: after and before treatment. Method of measurement: serologic tests.;Serum Cratinine. Timepoint: after and before treatment. Method of measurement: Biochemistry Tests.;SGPT. Timepoint: after and before treatment. Method of measurement: Biochemistry Tests.;Heart Functional Activity and Resistance Against Physical Activities. Timepoint: after and before treatment. Method of measurement: Exercise Test.;Hypertension. Timepoint: after and before treatment. Method of measurement: Blood Pressure Measurement Tests.	—

Measure

Time frame

Paintful joints. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;AlkP. Timepoint: after and before treatment. Method of measurement: serologic tests.;LDH. Timepoint: after and before treatment. Method of measurement: serologic tests.;SGOT. Timepoint: after and before treatment. Method of measurement: serologic tests.;Tachypnea. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Dyspnoeic. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Headache. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Organ edema. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Vomiting. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;Nausea. Timepoint: after and before treatment. Method of measurement: qualitative tests and quality of life tests.;BUN. Timepoint: after and before treatment. Method of measurement: serologic tests.;Serum Cratinine. Timepoint: after and before treatment. Method of measurement: Biochemistry Tests.;SGPT. Timepoint: after and before treatment. Method of measurement: Biochemistry Tests.;Heart Functional Activity and Resistance Against Physical Activities. Timepoint: after and before treatment. Method of measurement: Exercise Test.;Hypertension. Timepoint: after and before treatment. Method of measurement: Blood Pressure Measurement Tests.

—

Secondary

Measure	Time frame
Possible Drug Interventions. Timepoint: after treatment. Method of measurement: Quanlitative tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Younes Panahi

Baqiyatallah University of Medical Sciences

yunespanahi@yahoo.com+98 21 8248 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026